P2RY12 and atrial fibrillation: On the other hand, dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has been considered crucial to reduce the risk of in-stent stenosis in non-AF subjects undergoing PCI.35,36 In an attempt to balance the risk of recurrent ischaemia with risk of bleeding, guidelines recommend most AF patients to receive a short period of triple therapy.12 In our population, it was more likely for patients in the potent P2Y12 inhibitor group to claim a prescription for aspirin.